|
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<i>BRAF</i>V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC).
|
30374428 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
42 (37 PTC; 5 benign) surgical tissue samples were analysed for the BRAF V600E activating point mutation.
|
17298986 |
2007 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles.
|
25400776 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer subjects harboring RET/PTC rearrangements developed this cancer earlier than did cases with BRAF(V600E) mutation (P = 0.03).
|
18757433 |
2008 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation.
|
19883729 |
2010 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PTC cases were also examined for their BRAF(V600E) mutational status.
|
21730105 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Compared with patients harboring neither mutation, HRs (95% CIs) for PTC-specific mortality were 3.08 (0.87-10.84) for BRAF V600E alone; 8.18 (2.04-32.75) with TERT mutation alone; and 37.77 (12.50-114.09) with both mutations.
|
27581851 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid carcinoma samples with BRAF V600E mutation were shown to have higher glucose transporter 1, hexokinase II, carbonic anhydrase IX, and tumoral monocarbonylate transporter 4 expression levels.
|
28347233 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PTC status, measures of aggressiveness (e.g. tumor size) and BRAF V600E mutation were included as outcomes.
|
28772138 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001).
|
31455351 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600E BRAF mutation is emerging as an independent marker of papillary thyroid carcinoma aggressive behavior.
|
19693938 |
2010 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 benign nodules and in only 1/54 indeterminate nodules that, after histology, turned out to be at a papillary thyroid carcinoma.
|
25194426 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A high percentage of BRAF(V600E) alleles defines a PTC molecular subtype and predicts a poorer disease outcome.
|
22508706 |
2012 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of 47 intracerebral melanoma metastases and 21 primary papillary thyroid carcinomas were evaluated by direct sequencing of BRAF and by immunohistochemistry using the BRAF V600E mutation-specific antibody clone VE1.
|
21638088 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR assay for BRAF T1799A (V600E).
|
20607744 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
According to the morpho-molecular analysis (i.e., traditional cytology combined with BRAF V600E analysis) 74/90 (82.2%) patients could be assigned a definitive diagnosis of PTC.
|
19534623 |
2009 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Activating BRAF(T1799A) mutation is closely associated with a papillary thyroid carcinoma (PTC) histotype.
|
17044028 |
2007 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Activating mutations in the valine-to-glutamic acid substitution at position 600 of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF-1) gene are detected frequently in patients with papillary thyroid carcinoma (PTC).
|
23192956 |
2013 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Activating mutations in the BRAF gene, primarily at V600E, are associated with poorer outcomes in patients with papillary thyroid cancer.
|
17878251 |
2007 |